ARTICLE | Company News
NanoBio, Merck deal
December 19, 2011 8:00 AM UTC
The partners will evaluate combining Merck's respiratory syncytial virus (RSV) antigen and NanoBio's NanoStat adjuvant technology for use as an intranasal vaccine. Merck has an option to license non-e...